Monocyte-derived dendritic cells from breast cancer patients are biased to induce CD4(+)CD25(+)Foxp3(+) regulatory T cells JOURNAL OF LEUKOCYTE BIOLOGY, BETHESDA, v. 92, n. 3, pp. 673-682, SEP, 2012 ϩ , suppressed mitogen-stimulated T cells. Contrastingly, Mo-DCs from healthy donors induced a stronger proliferative response, a low frequency of CD4 ϩ CD25 ϩ Foxp3 ϩ with no suppressive activity. Furthermore, healthy Mo-DCs induced higher levels of IFN-␥, whereas the Mo-DCs of patients induced higher levels of bioactive TGF-␤1 and IL-10 in cocultures with allogeneic T cells. Interestingly, TGF-␤1 blocking with mAb in cocultures was not enough to completely revert the Mo-DCs of patients' bias toward Treg induction. Altogether, these findings should be considered in immunotherapeutic approaches for cancer based on Mo-DCs. J. Leukoc. Biol. 92: 673-682; 2012.
Introduction
DCs are unique, professional APCs adapted to initiate, coordinate, and regulate adaptive immune responses by inducing naive T cells' differentiation [1, 2] into Th1 [3] , Th2 [4] , Th17 [5] , and other CD4 ϩ cell subtypes [6] . Recent data suggest that DCs are also crucial for the induction and maintenance of T cell tolerance and have important physiological roles in the prevention of autoimmunity [7] . Furthermore, DCs can contribute to the subversion of the immune responses in cancer [8, 9] , in ways that could resemble their role in maintaining self-tolerance.
It did not take long after the discovery of DCs for their potential in cancer immunotherapy to be recognized [10, 11] . However, as DCs have the potential to induce not only immunity but also immune tolerance, depending on their functional status [12] , many attempts to use DCs in cancer immunotherapy may have failed to reach all of the expected success as a result of a possible functional deficit of the cells used. Further, many studies have demonstrated that DCs are essential for Treg induction in vitro [13, 14] , apparently depending on various distinct mechanisms [15] but also frequently, on external sources of cytokines [16] .
Optimization of DC differentiation protocols has focused largely on the capacity of human DCs to improve protective immunity against cancer [17] ; however, their ability to induce regulatory cells concurrently has received less attention. Tregs contribute to the maintenance of immunologic self-tolerance [18] and play a relevant role in immune responses to infectious agents [19, 20] . Harnessing their function could help in the management of transplantation reactions, whereas their action can represent an obstacle for successful immunotherapy in patients with cancer [21, 22] . Although CD8 ϩ Tregs have been described [23] , most studies focused on CD4 ϩ Tregs.
These have been described on the basis of their origin and generation [24] and mechanism of action [25] . Inducible Tregs that are comprised of IL-10-producing Tr1 cells [26] , TGF-␤-producing Th3 cells [27] , and inducible Foxp3 ϩ T cells [28] , described in different situations, including cancer [29 -31] , seem to depend largely on the context of antigen presentation, a phenomenon where DCs play a most relevant role. DCs are affected by the presence of tumors [32, 33] . Various observations indicate a deficient functional activity of these cells with defective stimulation of immune responses as a re-sult of a decreased frequency of functionally competent mDCs (semimature or iDC induction) within tumors. These DCs are characterized, mainly, by a poor up-regulation of MHC class II and costimulatory molecules and absent or low-production proinflammatory cytokines, such as IL-12, thus favoring tumor evasion from the immune response. Another functional consequence of tumor-DC interactions could be the favoring of the already-described expansion of CD4 ϩ CD25 ϩ Foxp3 ϩ Tregs in patients with solid tumors. Indeed, some studies have shown the active participation of DCs in the induction of Foxp3 expression by CD4
ϩ T cells in humans [34] and mice [35] . However, DCs from healthy donors only seem to induce Tregs in the presence of TGF-␤ [36] or overstimulation with anti-CD3, anti-CD28, and IL-2.
Although DCs from cancer patients are recognized as functionally deficient, it is not so clear whether Mo-DCs from these patients show similar deficiencies. Here, we generated DCs (Mo-DCs) from breast cancer patients and show that these are strongly biased to the induction of functional Tregs, thus possibly contributing to the maintenance of a pro-tumor immune status in the patients and possibly, posing an obstacle for DCbased therapeutic approaches for cancer.
MATERIALS AND METHODS

Eligibility criteria
Patients, from the Mastology Center at the Perola Byington Hospital (Sao Paulo, Brazil), with a recent histopathological diagnosis of invasive breast carcinoma and who had not received chemotherapy, radiotherapy, or immunotherapy before study enrollment, were included. Those with uncontrolled metastatic lesions in the brain, with hypercalcemia, with other previous or concomitant neoplasia, who were pregnant or lactating, with autoimmune diseases, or were HIV-seropositive were excluded from the study. As controls, we chose healthy, female volunteers over 20 years old. All patients and healthy volunteers gave written, informed consent. The protocol was approved by the Institutional Ethics Committee (2009/902 CEP).
DC generation
PBMCs were separated from blood collected in heparin (50 U/ml) by centrifugation over Ficoll-Hypaque (Amersham Pharmacia Biotech, Uppsala, Sweden). Mononuclear cells were resuspended and seeded in culture sixwell plates in RPMI-1640 culture medium (Gibco, Grand Island, NY, USA), supplemented with 10% FCS (Gibco) plus antibiotic-antimycotic (100 U/ml penicillin, 100 g/ml streptomycin, and 25 g/ml amphotericin; Gibco). After that, culture plates were incubated at 37°C overnight. In case of monocyte use, after overnight incubation, nonadherent cells were removed, and the adhered monocytes were harvested, washed, and used for the experiments. In case of Mo-iDC use, nonadherent cells were removed, the medium was replaced, and GM-CSF (50 ng/ml; R&D Systems, Minneapolis, MN, USA) and IL-4 (50 ng/ml; R&D Systems) were added. Mo-iDCs were harvested after 7 days, without any additional manipulation, phenotypically characterized, and used in cocultures. Mo-mDCs were harvested at Day 7, after receiving maturation stimuli at Day 5 with sCD40L (1 mg/mL; Invitrogen, Carlsbad, CA, USA); a cytokine cocktail containing IL-1␤ (10 ng/ml; R&D Systems), IL-6 (10 ng/ml; R&D Systems), and TNF-␣ (10 ng/ ml; R&D Systems); only TNF-␣ (50 ng/ml; R&D Systems); or LPS (500 ng/ ml; Escherichia coli 0111:B4; Sigma-Aldrich, St. Louis, MO, USA).
For some experiments, the starting cell population was that of CD14 
T cell proliferation by CFSE dilution
Isolated CD3
ϩ T cells were labeled with 5 M CFSE and cultivated with patients or healthy Mo-iDCs. After 5 days, lymphocytes were stained with anti-CD4 and anti-CD8 antibodies, and CFSE dilution was determined by flow cytometry analysis. PHA was used as a polyclonal-positive stimulus. At least 20,000 events were acquired/antibody analyzed. Lymphocytes. Foxp3 expression in T cells was assessed using the antihuman Foxp3 staining kit (Clone 236A/E7; eBioscience, San Diego, CA, USA). Mouse IgG1 (BD Biosciences) was used as isotype control in all intracellular staining analyses. Samples were also stained with CD25, CD3, CD4, CTLA4, CD127, and CD45RA (BD Biosciences). At least 20,000 events were acquired/antibody analyzed.
Mo-DCs and T cell cocultures
Cytokine assay
Coculture supernatants were harvested after 5 days, and IFN-␥ (BD PharMingen, San Diego, CA, USA), IL-10 (BD PharMingen), and bioactive TGF-␤1 (eBioscience) were quantified by sandwich ELISA, according to the manufacturers ' instructions. OD was determined in a VersaMax microplate ELISA reader and converted to pg/ml using a standard curve and SoftMax Pro software.
Suppression assay
To assess the ability of T cells, generated after cocultures with Mo-iDCs from patients and controls, to suppress other T cell responses, CD25 ϩ cells were sorted magnetically from cocultures using the CD25 Microbeads II kit (Miltenyi Biotec) and added to allogeneic, healthy, CFSE-labeled PBMCs (1ϫ10 5 /well) at a 1:10 ratio in 96-well U-bottom plates in the presence of PHA (1 g/ml) at 37°C and 5% CO 2 . On Day 3, the cells were harvested, and the T cell proliferative response was determined by flow cytometry, evaluating the dilution of CFSE.
TGF-␤ blocking in cocultures
To block TGF-␤ activity in cocultures of Mo-DCs and T lymphocytes, 80 ng/ml neutralizing anti-TGF-␤ (R&D Systems) or control IgG mAb (BD Biosciences) were added on Day 0 of cultures.
Statistical analysis
Results were checked for normality by the Kolmogorov-Smirnov test, and comparisons between results obtained from healthy donors and breast cancer patients were performed by a two-tailed unpaired t-test (*PϽ0.05; **PϽ0.01; ***PϽ0.0001). Effects of neutralizing anti-TGF-␤ were compared using the paired t-test (*PϽ0.05; **PϽ0.01). Phenotype of monocytes, MoiDCs, and Mo-mDCs was compared using the one-way ANOVA test with the Tukey post-test.
RESULTS
Mo-iDC cells from patients are phenotypically different from those derived from healthy donors
Mo-iDCs were generated in vitro from breast cancer patients (nϭ9) and from healthy donors (nϭ5) by culture for 7 days in the presence of IL-4 and GM-CSF. Already at the FSC and SSC profiles of the cells, we noticed that the Mo-iDCs of patients represented a nonhomogeneous population compared with the relatively homogeneous cells of healthy donors. On the other hand, the analysis of CD14 and HLA-DR expression indicated similar frequency of cells with a Mo-iDC phenotype (CD14-HLA-DR ϩ ) in both groups (healthy donors: 87.3%Ϯ0.3 vs. patients: 87.1%Ϯ3.0; Fig. 1A ). Of the molecules evaluated in DCs, CD80, HLA-DR, and CD11c were not significantly different between healthy donors and patients, but the expression of CD86 and CD123 clearly distinguished these groups, both in frequency of positive cells (CD86ϭhealthy Fig. 1A-C) . On the other hand, the expression of CD1a was significantly lower in frequency (healthy donors: 68Ϯ13 vs. patients: 38.1Ϯ18; PϽ0.05) and the CD83 activation marker, lower in MFI (healthy donors: 68Ϯ16 vs. patients: 33.2Ϯ24; PϽ0.05) in Mo-iDCs from patients (Fig. 1A-C) . Nevertheless, the maturation status of both cell populations was similar, with their immature phenotype indicated by low values of MFI for all costimulatory molecules tested.
In the ELISA assay of the culture supernatants (at Day 5), for the production of IL-10 and bioactive TGF-␤1, although Mo-iDC patients seemed to produce higher levels of the latter (healthy donors: 107.4Ϯ4.73 pg/ml vs. patients: 203.3Ϯ71.7 pg/ml; PϽ0.05; Fig. 1D ), the difference was not significant.
Mo-iDCs from patients induce lower lymphocyte activation and proliferation but higher proportions of CD4
؉ CD25 ؉
Foxp3
؉ cells
To investigate further the possible functional deviation of the Mo-iDCs of patients, our next step was the analysis of their ability to activate and stimulate lymphocyte proliferation in Fig. 2A-C Fig. 2A-C) .
When Mo-iDCs were used to stimulate allogeneic CD3 Fig. 2D-F Fig. 3A and B) . To exclude possible nonDCs contaminating the cultures, we differentiated Mo-iDCs from CD14
ϩ -preisolated cells. In coculture with allogeneic T lymphocytes, these induced the same Treg frequency as the nonisolated population (Fig. 3C) . Accordingly, cocultures with patient Mo-iDCs showed increased concentrations of IL-10 (healthy donors: 14.0Ϯ2.6 pg/ml vs. patients: 61.8Ϯ28.1 pg/ ml; PϽ0.05) and bioactive TGF-␤1 (healthy donors: 57.6Ϯ3.3 pg/ml vs. patients: 298.1Ϯ129 pg/ml; PϽ0.05), whereas those with healthy Mo-iDC donors presented higher levels of IFN-␥ (healthy donors: 471.8Ϯ620 pg/ml vs. patients: 14.8Ϯ15.6 pg/ ml; PϽ0.05; Fig. 3D ).
Tregs induced by Mo-iDCs from cancer patients showed a reduced proliferative activity in the cocultures and are able to suppress T lymphocyte responses to PHA T lymphocytes were separated, labeled with CFSE, and cocultured with Mo-iDCs. After 6 days, proliferation was evaluated by CFSE dilution within Foxp3 ϩ and Foxp3 neg cells. As expected, proliferation of Foxp3 ϩ cells was significantly lower than that of Foxp3 neg cells in healthy Mo-DC-stimulated cultures of donors and patients (Fig. 4A) (Fig. 4A, bottom graphs) . 
To test the suppressive function of lymphocytes stimulated by different Mo-iDCs, CD25
ϩ cells were isolated by magnetic microbeads (97% of purity) from the healthy Mo-iDC-T cell cocultures of patients and added (at a 1:10 ratio) to allogeneic PBMCs, previously labeled with CFSE and stimulated with PHA. After 3 days in culture, cells were analyzed by cytometry for CFSE dilution. CD25 ϩ cells from the Mo-iDC-T cocultures of patients inhibited mitogen-induced T cell proliferation, whereas cells from the healthy coculture of donors were stimulatory in the same settings ( Fig. 4B and C) .
TGF-␤ neutralization with mAb partially inhibits Treg induction by Mo-iDCs from breast cancer patients
TGF-␤ is recognized as a relevant cytokine for the induction of Tregs and is produced in high levels by Mo-DCs from breast cancer patients. Therefore, we tested whether a neutralizing antibody against this cytokine was able to inhibit Treg generation by Mo-DCs from patients cocultured with allogeneic CD4 ϩ -isolated lymphocytes. Indeed, the Mo-iDC-T cell cocultures of patients treated with the neutralizing antibody presented significantly higher cell proliferation (Fig. 5A) , without reducing the induced CD25 ϩ T cell proportion (Fig. 5B) . Beyond that, the presence of anti-TGF-␤ antibodies also led to significantly lower frequency (Fig. 5C ) and absolute number (Fig. 5D ) of CD4 ϩ CD25 ϩ Foxp3 ϩ CD127 low cells in cocultures, however, not in a similar frequency to levels induced by healthy Mo-iDCs.
DCs differentiated from the monocytes of breast cancer patients present a bias for the induction of Tregs even after maturation stimulus
Maturation of DCs is associated with a decrease in their ability to induce regulation. Therefore, monocytes and Mo-iDCs and
sCD40L, cocktail, TNF-␣, and LPS-treated Mo-iDCs from breast cancer patients were used as stimulators of allogeneic T cells to analyze the generation of CD4
ϩ CD25 ϩ Foxp3 ϩ cells. The phenotypic analysis demonstrated the dynamic increase of molecules (MFI) during monocyte-to-Mo-DC differentiation (Fig. 6A) . In functional assays, healthy Mo-mDC TNF-␣ induced a higher frequency of CD25 ϩ cells (Fig. 6B ) and lower frequency (Fig. 6C ) and absolute number (Fig. 6D ) of CD4 ϩ CD25 ϩ Foxp3 ϩ cells, as compared with all groups of the activated Mo-mDCs of patients. Moreover, analysis between the APCs of patients showed a reduced ability of monocytes to induce CD4 ϩ CD25 ϩ Foxp3 ϩ in comparison with Mo-iDCs and all Mo-mDC groups in frequency and absolute number (Fig. 6C  and D) . Regarding the activation status between Mo-DCs from patients, Mo-mDCs LPS were the only ones capable of significantly increasing the frequency of CD25 ϩ cells (Fig. 6B ) and reducing CD4 ϩ CD25 ϩ Foxp3 ϩ frequency (Fig. 6C ) in relation to the ability of Mo-iDCs; however, the absolute number of CD4 ϩ CD25 ϩ Foxp3 ϩ induced was not altered (Fig. 6D) . Furthermore, the absolute number of induced Tregs was not different, comparing all activation stimulus used in the Mo-iDCs of patients (Fig. 6D) , failing to revert the bias present in those cells.
DISCUSSION
We show here that Mo-DCs from cancer patients have a bias toward the induction of Tregs, a characteristic that is bound to impair the effectiveness of any therapeutic trial based on the cells of these patients. Indeed, Tregs are recognized as central in the maintenance of tolerance to self [37] but may also be involved in the failure of the immune system to eliminate or control infections [19, 20] and tumors [21] and to respond to therapeutic vaccination [22] . Thus, the optimization of the DC phenotype, when these are used for therapeutic vaccination in cancer, is a crucial point for the achievement of better clinical responses.
Here, we induced the differentiation of blood monocytes obtained from breast cancer patients and from healthy donors into DCs, cultivating blood precursors in the presence of GM-CSF and IL-4, an established protocol for the generation of Mo-DCs [38] . Interestingly, under phase-contrast microscopy (data not shown) and by flow cytometry, Mo-iDCs, obtained from patients, presented a distinct morphology, being quite heterogeneous in FSC and SSC. On other hand, the frequency of cells within the FSC and SSC gate characteristic of DCs was similar between patients and healthy donors, as was the frequency of CD14 neg HLA-DR ϩ cells within these gates, suggesting, thus, that the overall differentiation process was not affected significantly in the cells of cancer patients.
Although the frequency of Mo-iDCs was similar, cells derived from patients showed a higher frequency of CD86 costimulatory molecule expression and the classical plasmacytoid marker, CD123. Furthermore, whereas cells derived from healthy donors presented a single population of CD86 ϩ cells, with intermediate fluorescence intensity, those derived from patients seemed to be divided in two subpopulations: one with high and the other with low levels of CD86 expression. Indeed, the modulation of costimulatory molecules in APCs, particularly in DCs, seems to be essential to initiate and coordinate the nature of T cell responses [1] . CD86 and CD80 bind to stimulatory (CD28) and inhibitory (CTLA4) receptors on T cells with different affinities [39] . In human DCs, the induction and up-regulation of CD86 were shown to influence T cell activation significantly [40] , whereas studies in knockout mice have indicated that the ability of DCs to generate/expand Treg subsets can be related to the balance of CD80 and CD86 [41, 42] . Our data indicate that the Mo-iDCs of patients present an altered CD86 pattern of expression and are poor T cell activators but very good Treg expansors/activators, suggesting that the modulation of costimulatory molecule expression could, indeed, be a pathway for the deviation of DC function in cancer patients. Actually, we have already observed an altered expression of CD86 in Mo-DCs from advanced cancer patients that was, apparently, corrected by an immunotherapeutic approach [9] . Simultaneously, we also need to consider the higher MFI expression of PD-L1 in Mo-iDCs from cancer patients as possibly involved in the tolerogenic function of these cells, as in murine models, the expression of this molecule by DCs has been related to Foxp3
ϩ Treg via the PD-1R [43] . Interestingly, in humans, recent studies describe PD-L1 overexpression by peritumoral monocytes [44] and by tumor cells [45] . Furthermore, the high expression of CD123 molecules deserves investigation, as it has been reported that CD123 expression is related to a high expression of IDO, which confers a tolerogenic function to human myeloid DCs [46] and seems to be involved in the recruitment of Foxp3 ϩ cells to ovary tumor sites [47] . Therefore, although the ability of DCs to induce Treg activation depends on the balance of these various costimulatory molecules [48] , the exact role of the balance between these molecules, mainly in human DCs and particularly, in cancer patients, is still unclear.
Additionally to the membrane phenotype differences, IL-10 and bioactive TGF-␤1 cytokine production by the Mo-iDCs of patients were also characteristic, as elevated levels of both of these suppressor cytokines were found in their culture supernatants when compared with healthy Mo-iDCs. These cytokines are also involved in the commitment of näive T cells to suppressive properties [49] , with IL-10 involved in the generation of Tr1 cells and TGF-␤ in the generation of Th3 Foxp3 ϩ cells. TGF-␤ is a multifunctional cytokine that regulates T cell growth and development [50] , inhibits IL-2 production, and has potent, antiproliferative effects on CD4 ϩ T cells [51] , principally by inducing Tregs [28, 36, 52] , thus providing a possible explanation for the preferential generation/expansion of Tregs by Mo-iDCs from cancer patients. Indeed, the addition of a neutralizing antibody against this cytokine in cocultures of the Mo-DCs of patients and allogeneic T cells allowed a significantly higher proliferation of T cells, which also presented a significantly lower frequency of CD4 ϩ CD25 ϩ Foxp3 ϩ cells. It is noteworthy, though, that the addition of the neutralizing anti-TGF-␤1 antibody was not enough to completely revert the induction of Tregs by the Mo-DCs of patients, thus suggesting the contribution of more than one mechanism for the generation of Tregs by the Mo-DCs of patients.
It is noteworthy that the CD25 ϩ cells, generated by coculture with the Mo-iDCs of patients, were able to suppress a mitogen-induced T cell proliferation, in contrast with CD25 ϩ cells stimulated by healthy donor Mo-iDCs that had no suppressive activity. Considering that the CD25 marker selected activated cells and Tregs, we thus confirm the suppressive activity of CD25 ϩ Foxp3 ϩ lymphocytes induced by the Mo-iDCs of patients in vitro. Indeed, Foxp3 ϩ T cells are phenotypically and functionally heterogeneous and may contain Foxp3 low non-Tregs (30 -50% of total CD4 ϩ Foxp3 ϩ T cells) that can produce proinflammatory cytokines [53] , a phenomenon that could explain the lack of suppressive activity by these cells when induced by the healthy DCs of donors.
Although interesting, these data could still be considered less significant, as the bias was noted when Mo-iDCs were studied, a population whose ability to induce Tregs has long been described [13, 14] . Furthermore, as Mo-mDCs are used in therapeutic protocols for cancer, one could argue that the phenotype of immature cells is of lesser relevance. Notwithstanding the fact that the bias was noted when immature cells of healthy controls and patients were compared, thus indicating a phenomenon beyond the simple maturation status of the cell, we decided to induce the Mo-DCs of the maturation of patients (using sCD40L, a cytokine cocktail, TNF-␣, and LPS) and then, evaluate their ability to induce Tregs, also comparing it with that of monocytes. In these experiments, we noted that Mo-mDCs from patients conserved the bias toward the induction of a similar number of Tregs, indicating the existence of a profound alteration of the monocytes of patients, which cannot be corrected easily by standard culture protocols. Besides that, it is also relevant that monocytes from healthy donors and from patients initially present a similar capacity to induce CD4 ϩ CD25 ϩ Foxp3 ϩ T lymphocytes. This capacity, however, decreases in the cells of healthy donors, as they differentiate toward DCs (as one would expect), but increases in cells of patients. Taken together, our data show important differences in phenotype and function of DCs derived from cancer patient monocytes that appear to be dependent of their surface phenotype and pattern of cytokine induction/production. These features could have a definitive role in the tumor-escape mechanism. If the apparent bias of Mo-DCs from cancer patients cannot be corrected by targeted in vitro manipulations, the effectiveness of cancer vaccination strategies based on these cells would probably be compromised significantly. On the other hand, the determination of the mechanisms, through which tumors are able to modify the circulating ability of monocytes to differentiate in vitro into DCs, could point to new, tumor-escape strategies, whose identification could provide new targets to be considered in immunotherapeutic approaches to cancer. 
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